Website
https://dataportal.arc.gov.au/NCGP/API/grants/LP140100142
Funding Status
Closed
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Funded Activity Summary
Drug Targeting to Immune Cells Using Modified Inulin Particles. Vaxine Pty Ltd is an Australian biotechnology company that has discovered specific particulate forms of inulin that are efficiently internalised by human immune cells. This project aims to exploit cell migration to injury and infection sites by attaching drugs to inulin particles creating a targeted drug delivery system. This system will transport drugs specifically to afflicted areas, reducing systemic concentrations of drugs and hence the risks of dose related side effects. This project has potential both to improve healthcare and to encourage the growth of expertise in the biotechnology industry in Australia.Funded Activity Details
Start Date: 05-2015
End Date: 06-2019
Funding Scheme: Linkage Projects
Funding Amount: $330,000.00
Funder: Australian Research Council
Research Topics
ANZSRC Field of Research (FoR)
Pharmaceutical Sciences | Medical Biotechnology | Medical Biotechnology not elsewhere classified | Characterisation of Biological Macromolecules |
ANZSRC Socio-Economic Objective (SEO)
Human Pharmaceutical Treatments (e.g. Antibiotics) | Veterinary Pharmaceutical Treatments (e.g. Antibiotics)
